BioVie has enrolled the first patient in its Phase 2 SUNRISE-PD trial evaluating bezisterim, an anti-inflammatory and insulin-sensitizing drug candidate, in early-stage Parkinson's disease patients who haven't received carbidopa/levodopa treatment.
The FDA has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour levodopa-based infusion for advanced Parkinson's disease.
A device-assisted therapy delivering dopamine directly to the brain shows potential in treating Parkinson's disease by improving symptom control without dyskinesia.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.